Bildschirmfoto_2021-12-09_um_13.07.31.png

German Apogenix AG has received a €26m in funding for a pivotal Phase III study of its CD95 ligand blocker asunercept for the treatment of COVID-19 patients.

© Adendra Therapeutics

The 2021 spin out of London-based Francis Crick Institute is the very first UK company formation deal of life sciences investor ATP (Apple Tree Partners). 

Swedish Oncopeptides has had a new CEO since mid-November. Jakob Lindberg has taken over the position from Marty J. Duvall again. He has left the company.

2021.10.07_EMEA_Whitepaper_Banner_Ads_Strategic-CDMO-partnerships.jpg

Abstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:

2021.10.07_EMEA_Whitepaper_Banner_Ads_Strategic-CDMO-partnerships.jpg

Abstract: This report provides a roadmap for assessing and selecting the right partner to get promising biological therapies to patients quickly. Criteria includes:

1000-563.jpg

Sino Biological, Inc. announced today that it has launched a panel of research reagents for the newly identified Omicron variant (B.1.1.529) of the SARS-CoV-2 virus, which quickly raised concerns around the world because of the high number of mutations it carries, especially the 30-plus mutations on the Spike protein.

Parentingupstream/Pixabay

Italian pharma company Recordati is putting €750m on the table to acquire UK-based specialty pharmaceutical company EUSA Pharma.

1868-1050.jpg

ANTIGENS Seasonal flu is a common infectious disease of the respiratory tract caused by influenza virus. There are four types of influenza virus, influenza type A, B, C, and D. The A and B types are of most interest to the medical community because they are the culprits for seasonal epidemics. Occasionally, influenza A, like the A/California/04/09 (H1N1) and A/Hong Kong/1/1968 (H3N2), can even cause global pandemics.

© Premier Research

Cancer immunotherapy exploits the body’s own immune system to fight against cancer. CAR-T cell therapy is one of the breakthrough approaches that involves re-engineering a patient’s own
T cells to recognize and eradicate cancer.

Picture: Pistoia Alliance

The pharmaceutical industry has made significant advances in collaboration over the past two years, and I have seen many examples amongst Pistoia Alliance members of the power of cooperative working. It is imperative that the industry continues to build on these successes.